{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:25:28Z","timestamp":1772861128048,"version":"3.50.1"},"reference-count":50,"publisher":"Bentham Science Publishers Ltd.","issue":"40","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Background-aim:<\/jats:title>\n<jats:p>In this narrative review, firstly we describe the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the pathogenesis of its infection in humans. Later, the importance of mast cells in SARS-CoV-2 infection and their role in Coronavirus Disease 2019 (COVID-19) will be discussed. SARS-CoV-2 is a transmissible agent frequently detected in some mammalian species and nowadays also in humans.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Literature data published in PubMed that covered mast cells' role in cytokine release syndrome and related manifestations of COVID-19 disease was reviewed by the authors independently and collectively. Recommendations for the management of cytokine release syndrome and related manifestations were made by the authors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Mast cells are concentrated in environments where they encounter viruses, bacteria, and toxins, especially in the skin, nasal mucosa, lungs, airways, gastrointestinal tract, and meninges, to prevent their entry into the human body. Once SARS-CoV-2 enters the host, it stimulates one of them, mast cells, together with pre-existing innate immune cells that form a defensive barrier in the submucosa of the respiratory tract and nasal cavities against pathogenic microorganisms. The roles of mast cells in SARS-CoV-2 -induced hyper inflammation and cytokine storms have recently been one of the hot topics mostly discussed in the literature.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Physicians should keep in mind the mast cells' role in cytokine release syndrome and related manifestations of COVID-19 disease. Mast cell-targeting therapies (eg, H1 and H2 receptor antagonists) can reduce the severity and course of the disease when used after complications associated with COVID-19 are suspected or seen.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612829666221027114123","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T07:22:33Z","timestamp":1666941753000},"page":"3261-3268","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mast Cell's Role in Cytokine Release Syndrome and Related Manifestations of\nCOVID-19 Disease"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-9561","authenticated-orcid":true,"given":"\u00d6ner","family":"\u00d6zdemir","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Allergy and Immunology, Sakarya University, Faculty of Medicine, Research and Training\nHospital of Sakarya University, Sakarya, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-502X","authenticated-orcid":true,"given":"Azize Yasemin","family":"G\u00f6ksu Erol","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, Faculty of Medicine, Akdeniz University,\nAntalya, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-1108","authenticated-orcid":true,"given":"\u00dcmm\u00fcg\u00fcls\u00fcm","family":"Dikici","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Allergy and Immunology, Sakarya University, Faculty of Medicine, Research and Training\nHospital of Sakarya University, Sakarya, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.14744\/etd.2020.99836","volume":"42","author":"\u00d6zdemir \u00d6.","year":"2020","unstructured":"\u00d6zdemir \u00d6.; Coronavirus Disease 2019 (COVID-19): Diagnosis and management (narrative review). Erciyes Med J 2020,42(3),242-247","journal-title":"Erciyes Med J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/1073858420941476","volume":"26","author":"Kempuraj D.","year":"2020","unstructured":"Kempuraj D.; Selvakumar G.P.; Ahmed M.E.; COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 2020,26(5-6),402-414","journal-title":"Neuroscientist"},{"key":"ref=3","first-page":"13","volume":"7","author":"\u00d6zdemir \u00d6.","year":"2020","unstructured":"\u00d6zdemir \u00d6.; Erkun O.; Solving puzzle of the immunopatho-genesis for management of COVID-19 disease. MOJ Immunol 2020,7(1),13-15","journal-title":"MOJ Immunol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.5471","volume":"251","author":"Bourgonje A.R.","year":"2020","unstructured":"Bourgonje A.R.; Abdulle A.E.; Timens W.; Angiotensin\u2010converting enzyme 2 (ACE2), SARS\u2010CoV \u20102 and the pathophysiology of coronavirus disease 2019 (COVID \u201019). J Pathol 2020,251(3),228-248","journal-title":"J Pathol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/iub.2552","volume":"73","author":"Lam H.Y.","year":"2021","unstructured":"Lam H.Y.; Tergaonkar V.; Kumar A.P.; Ahn K.S.; Mast cells: Therapeutic targets for COVID \u201019 and beyond. IUBMB Life 2021,73(11),1278-1292","journal-title":"IUBMB Life"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.immuni.2009.08.022","volume":"31","author":"Stelekati E.","year":"2009","unstructured":"Stelekati E.; Bahri R.; D\u2019Orlando O.; Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009,31(4),665-676","journal-title":"Immunity"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.3748\/wjg.v11.i44.7054","volume":"11","author":"\u00d6zdemir \u00d6.","year":"2005","unstructured":"\u00d6zdemir \u00d6.; Immunosurveillance function of human mast cell? World J Gastroenterol 2005,11(44),7054-7056","journal-title":"World J Gastroenterol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/jcp.57.1.108-a","volume":"57","author":"\u00d6zdemir O.","year":"2004","unstructured":"\u00d6zdemir O.; Sava\u015fan S.; The role of mast cells in bone marrow diseases. J Clin Pathol 2004,57(1),108-a-9","journal-title":"J Clin Pathol"},{"key":"ref=9","first-page":"LE9","volume":"12","author":"\u00d6zdemir O.","year":"2006","unstructured":"\u00d6zdemir O.; Mast cells and the tumor-associated neoangio-genesis. Med Sci Monit 2006,12(6),LE9-LE11","journal-title":"Med Sci Monit"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e1003783","DOI":"10.1371\/journal.ppat.1003783","volume":"9","author":"St John A.L.","year":"2013","unstructured":"St John A.L.; Influence of mast cells on dengue protective immunity and immune pathology. PLoS Pathog 2013,9(12),e1003783","journal-title":"PLoS Pathog"},{"key":"ref=11","first-page":"178","volume":"12","author":"Y\u0131lmaz E.A.","year":"2022","unstructured":"Y\u0131lmaz E.A.; \u00d6zdemir \u00d6.; Reflection from pathophysiology and role of immune system onto clinic table and management in SARS-CoV-2 infection. Sakarya Med J 2022,12(1),178-187","journal-title":"Sakarya Med J"},{"key":"ref=12","first-page":"9","volume":"34","author":"Kritas S.K.","year":"2020","unstructured":"Kritas S.K.; Ronconi G.; Caraffa A.; Gallenga C.E.; Ross R.; Conti P.; Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents 2020,34(1),9-14","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/infdis\/jix447","volume":"216","author":"Tissera H.","year":"2017","unstructured":"Tissera H.; Rathore A.P.S.; Leong W.Y.; Chymase level is a predictive biomarker of dengue hemorrhagic fever in pediatric and adult patients. J Infect Dis 2017,216(9),1112-1121","journal-title":"J Infect Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1073\/pnas.1105079108","volume":"108","author":"St John A.L.","year":"2011","unstructured":"St John A.L.; Rathore A.P.S.; Yap H.; Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci USA 2011,108(22),9190-9195","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/cells10071761","volume":"10","author":"Hafezi B.","year":"2021","unstructured":"Hafezi B.; Chan L.; Knapp J.P.; Cytokine storm syndrome in SARS-CoV-2 infections: A functional role of mast cells. Cells 2021,10(7),1761","journal-title":"Cells"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/cells10102754","volume":"10","author":"Murdaca G.","year":"2021","unstructured":"Murdaca G.; Di Gioacchino M.; Greco M.; Basophils and mast cells in COVID-19 pathogenesis. Cells 2021,10(10),2754","journal-title":"Cells"},{"key":"ref=17","first-page":"1629","volume":"34","author":"Conti P.","year":"2020","unstructured":"Conti P.; Caraffa A.; Tet\u00e8 G.; Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents 2020,34(5),1629-1632","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","volume":"27","author":"Zhou Z.","year":"2020","unstructured":"Zhou Z.; Ren L.; Zhang L.; Heightened innate immune responses in the respiratory tract of COVID\u201019 patients. Cell Host Microbe 2020,27(6),883-890.e2","journal-title":"Cell Host Microbe"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/JLB.4HI0221-087R","volume":"110","author":"Soria-Castro R.","year":"2021","unstructured":"Soria-Castro R.; Meneses-Preza Y.G.; Rodr\u00edguez-L\u00f3pez G.M.; Severe COVID\u201019 is marked by dysregulated serum levels of carboxypeptidase A3 and serotonin. J Leukoc Biol 2021,110(3),425-431","journal-title":"J Leukoc Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"650331","DOI":"10.3389\/fimmu.2021.650331","volume":"12","author":"Gebremeskel S.","year":"2021","unstructured":"Gebremeskel S.; Schanin J.; Coyle K.M.; Mast cell and eosinophil activation are associated with COVID-19 and TLR- mediated viral inflammation: implications for an anti-siglec-8 antibody. Front Immunol 2021,12,650331","journal-title":"Front Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2021.05.31.21255594","DOI":"10.1101\/2021.05.31.21255594","author":"Tan J.","year":"2021","unstructured":"Tan J.; Anderson D.E.; Rathore A.P.; Signatures of mast cell activation are associated with severe COVID-19. medRxiv 2021,2021.05.31.21255594","journal-title":"medRxiv"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.14744\/etd.2022.28938","volume":"44","author":"\u00d6zdemir \u00d6","year":"2022","unstructured":"\u00d6zdemir \u00d6; Dikici \u00dc.; Incidence of SARS-CoV-2 infection in asthma patients on omalizumab therapy. Erciyes Med J 2022,44(5)","journal-title":"Erciyes Med J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/ddg.14169","volume":"18","author":"Sch\u00f6n M.P.","year":"2020","unstructured":"Sch\u00f6n M.P.; Berking C.; Biedermann T.; COVID\u201019 and immunological regulations-from basic and translational aspects to clinical implications. J Dtsch Dermatol Ges 2020,18(8),795-807","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/j.jaip.2021.02.023","volume":"9","author":"Giannetti M.P.","year":"2021","unstructured":"Giannetti M.P.; Weller E.; Alvarez-Twose I.; COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J Allergy Clin Immunol Pract 2021,9(5),2083-2086","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","volume":"11","author":"Tang Y.","year":"2020","unstructured":"Tang Y.; Liu J.; Zhang D.; Xu Z.; Ji J.; Wen C.; Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol 2020,11,1708","journal-title":"Front Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-22094-5.","author":"Schimuzu M.","unstructured":"Schimuzu M.; (2019). Clinical features of cytokine storm syndrome. cytokine storm syndrome Springer Nature, Switzerland,31-42","journal-title":"cytokine storm syndrome"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"Guan W.","year":"2020","unstructured":"Guan W.; Ni Z.; Hu Y.; Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020,382(18),1708-1720","journal-title":"N Engl J Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"Chen G.","year":"2020","unstructured":"Chen G.; Wu D.; Guo W.; Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020,130(5),2620-2629","journal-title":"J Clin Invest"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijid.2020.09.016","volume":"100","author":"Afrin L.B.","year":"2020","unstructured":"Afrin L.B.; Weinstock L.B.; Molderings G.J.; COVID-19 hyper-inflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis 2020,100,327-332","journal-title":"Int J Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nri2782","volume":"10","author":"Abraham S.N.","year":"2010","unstructured":"Abraham S.N.; St John A.L.; Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010,10(6),440-452","journal-title":"Nat Rev Immunol"},{"key":"ref=31","first-page":"1633","volume":"34","author":"Theoharides T.C.","year":"2020","unstructured":"Theoharides T.C.; Conti P.; COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J Biol Regul Homeost Agents 2020,34(5),1633-1636","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaci.2020.06.009","volume":"146","author":"Valent P.","year":"2020","unstructured":"Valent P.; Akin C.; Bonadonna P.; Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol 2020,146(2),300-306","journal-title":"J Allergy Clin Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1515\/dx-2020-0005","volume":"8","author":"Afrin L.B.","year":"2021","unstructured":"Afrin L.B.; Ackerley M.B.; Bluestein L.S.; Diagnosis of mast cell activation syndrome: A global \u201cconsensus-2\u201d. Diagnosis (Berl) 2021,8(2),137-152","journal-title":"Diagnosis (Berl)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3389\/fimmu.2020.01130","volume":"11","author":"Ruscitti P.","year":"2020","unstructured":"Ruscitti P.; Berardicurti O.; Di Benedetto P.; Severe COVID-19, another piece in the Puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front Immunol 2020,11,1130","journal-title":"Front Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5582\/ddt.2020.03095","volume":"14","author":"Kazama I.","year":"2020","unstructured":"Kazama I.; Stabilizing mast cells by commonly used drugs: A novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther 2020,14(5),259-261","journal-title":"Drug Discov Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijid.2021.09.043","volume":"112","author":"Weinstock L.B.","year":"2021","unstructured":"Weinstock L.B.; Brook J.B.; Walters A.S.; Goris A.; Afrin L.B.; Molderings G.J.; Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis 2021,112,217-226","journal-title":"Int J Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","volume":"8","author":"Molderings G.J.","year":"2013","unstructured":"Molderings G.J.; Haenisch B.; Bogdanow M.; Fimmers R.; N\u00f6then M.M.; Familial occurrence of systemic mast cell activation disease. PLoS One 2013,8(9),e76241","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"574862","DOI":"10.3389\/fimmu.2020.574862","volume":"11","author":"Motta Junior J.S.","year":"2020","unstructured":"Motta Junior J.S.; Miggiolaro A.F.R.S.; Nagashima S.; Mast cells in alveolar septa of COVID-19 patients: A pathogenic pathway that may link interstitial edema to immunothrombosis. Front Immunol 2020,11,574862","journal-title":"Front Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1212\/WNL.0000000000009937","volume":"95","author":"Romero-S\u00e1nchez C.M.","year":"2020","unstructured":"Romero-S\u00e1nchez C.M.; D\u00edaz-Maroto I.; Fern\u00e1ndez-D\u00edaz E.; Neurologic manifestations in hospitalized patients with COVID-19. Neurology 2020,95(8),e1060-e1070","journal-title":"Neurology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/jcm9061917","volume":"9","author":"Lechowicz K.","year":"2020","unstructured":"Lechowicz K.; Dro\u017cd\u017cal S.; Machaj F.; COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med 2020,9(6),1917","journal-title":"J Clin Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4049\/jimmunol.1000273","volume":"185","author":"Ramos L.","year":"2010","unstructured":"Ramos L.; Pe\u00f1a G.; Cai B.; Deitch E.A.; Ulloa L.; Mast cell stabilization improves survival by preventing apoptosis in sepsis. J Immunol 2010,185(1),709-716","journal-title":"J Immunol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.14235\/bas.galenos.2020.4758","volume":"8","author":"Arsoy H.E.M.","year":"2020","unstructured":"Arsoy H.E.M.; \u00d6zdemir \u00d6.; Current therapeutic interventions for COVID-19. Bezmialem Sci 2020,8(3),105-116","journal-title":"Bezmialem Sci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18678\/dtfd.856165","volume":"23","author":"Engin M.M.N.","year":"2021","unstructured":"Engin M.M.N.; \u00d6zdemir \u00d6.; Potential immunological treatments in COVID-19 patients. Duzce Medical Journal 2021,23(1),1-9","journal-title":"Duzce Medical Journal"},{"key":"ref=44","first-page":"111","author":"K\u0131l\u0131nc E.","year":"2020","unstructured":"K\u0131l\u0131nc E.; K\u0131l\u0131nc Y.B.;  Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection 2020,111-119","journal-title":"Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000438605","volume":"38","author":"Baba A.","year":"2016","unstructured":"Baba A.; Tachi M.; Ejima Y.; Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing properties. Cell Physiol Biochem 2016,38(1),15-27","journal-title":"Cell Physiol Biochem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.pharep.2016.09.005","volume":"68","author":"Mori T.","year":"2016","unstructured":"Mori T.; Abe N.; Saito K.; Hydrocortisone and dexame-thasone dose-dependently stabilize mast cells derived from rat peritoneum. Pharmacol Rep 2016,68(6),1358-1365","journal-title":"Pharmacol Rep"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"633680","DOI":"10.3389\/fphar.2021.633680","volume":"12","author":"Malone R.W.","year":"2021","unstructured":"Malone R.W.; Tisdall P.; Fremont-Smith P.; COVID-19: Famotidine, histamine, mast cells, and mechanisms. Front Pharmacol 2021,12,633680","journal-title":"Front Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"Xu X.","year":"2020","unstructured":"Xu X.; Han M.; Li T.; Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020,117(20),10970-10975","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=49","first-page":"143","volume":"28","year":"2020","unstructured":"Vademecum for the treatment of people with COVID-19 Lombardy Section Italian Society Infectious And Tropical Diseases2020,28(2),143-152","journal-title":"Vademecum for the treatment of people with COVID-19"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"Zhang C.","year":"2020","unstructured":"Zhang C.; Wu Z.; Li J.W.; Zhao H.; Wang G.Q.; Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020,55(5),105954","journal-title":"Int J Antimicrob Agents"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221027114123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210415\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612829666221027114123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:16:11Z","timestamp":1691727371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210415\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":50,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612829666221027114123","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}